28/11/2023
Brand X provides smooth, sustained 24-hour coverage, enabling confident prescription for long-term blood pressure control in resistant hypertension. Findings from the Phase 3 RESIST-HTN trial confirm substantial systolic and diastolic BP lowering with unwavering efficacy over both nighttime and early morning periods.
Trial Design
The RESIST-HTN trial demonstrated Brand X's efficacy in 441 resistant hypertension patients adding Brand X versus 230 patients on placebo. All were already taking a 3-drug regimen of an ACE inhibitor or ARB, calcium channel blocker and thiazide diuretic but were still uncontrolled. This robust double-blind study assessed the benefit of Brand X over 12 weeks.
Efficacy Results
The primary endpoint was change in trough clinic systolic blood pressure (SBP) from baseline to week 12. Results showed Brand X patients achieved significantly greater SBP reductions of -16.3 mmHg versus -3.1 mmHg for placebo (p<0.001). Brand X also lowered diastolic BP more than placebo, -9.7 mmHg versus -1.9 mmHg (p<0.001).
Notably, 66% of Brand X patients reached BP control vs only 22% with placebo, highlighting superior rates of durable 24-hour coverage.
Safety Outcomes
The safety profile of Brand X remained consistent with the well-characterized AE profile of ACE inhibitors in hypertensive patients. Overall adverse events were similar between groups. No new risks were identified, supporting long-term use of Brand X for maintaining unwavering BP lowering in this difficult-to-treat population.
Conclusions
RESIST-HTN demonstrated Brand X is effective as add-on therapy for resistant hypertension patients requiring smooth 24-hour BP control. The combination of enhanced, around-the-clock BP reductions and a proven safety profile warrant strong consideration of Brand X for improving outcomes in hard-to-control resistant hypertension.